kineret and Humira pen crohn s disease starter package Interactions

Interactions between kineret(anakinra) and Humira pen crohn s disease starter package (adalimumab)

anakinra and adalimumab (Major Drug-Drug)

GENERALLY AVOID: The use of an interleukin-1 blocker in combination with a tumor necrosis factor (TNF) blocker may increase the risk of neutropenia and serious infections, possibly due to additive immunosuppressive effects. In a clinical study, neutropenia occurred in 3% and serious infections in 7% of patients receiving the combination (n=58). No added benefit has been observed with the combination relative to either agent alone.

MANAGEMENT: Concomitant use of an interleukin-1 blocker and a TNF blocker is not recommended.